Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment Research

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a low 5-year survival rate (13%) and limited treatment efficacy.
• Dense stroma and heterogeneous tumor microenvironment (TME) contribute to poor responses to chemotherapy and immunotherapy.
• Current therapies targeting PDAC stroma or immune responses show limited clinical success.

Purpose of the Study:

• To review the heterogeneous elements of the PDAC tumor microenvironment (TME).
• To discuss the potential of combination therapies targeting TME heterogeneity.
• To explore how molecular stratification can enhance treatment responses.

Main Methods:

• Literature review of PDAC tumor microenvironment (TME) components.
• Analysis of current and emerging therapeutic strategies targeting the TME.
• Discussion of combination therapy approaches and molecular stratification.

Main Results:

• The PDAC TME is characterized by significant heterogeneity.
• Preclinical strategies targeting the TME show promise but often fail in clinical translation.
• Combination therapies and molecularly stratified approaches are proposed to overcome treatment resistance.

Conclusions:

• Targeting the heterogeneous PDAC TME is crucial for improving therapeutic efficacy.
• Combination therapies tailored to individual TME profiles hold significant potential.
• Molecular stratification may optimize patient selection for targeted and combination treatments.